Polatuzumab Vedotin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Polatuzumab Vedotin |
| DrugBank ID | DB12240 |
| Brand Names (EU) | Polivy |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.34% |
Approved Indication (EMA)
Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HER2 positive breast carcinoma | 99.34% | DL |
| 2 | progesterone-receptor positive breast cancer | 98.91% | DL |
| 3 | normal breast-like subtype of breast carcinoma | 98.91% | DL |
| 4 | breast tumor luminal A or B | 98.89% | DL |
| 5 | progesterone-receptor negative breast cancer | 98.86% | DL |
| 6 | drug-induced osteoporosis | 98.84% | DL |
| 7 | acne (disease) | 97.48% | DL |
| 8 | antithrombin deficiency type 2 | 97.05% | DL |
| 9 | heparin cofactor 2 deficiency | 96.86% | DL |
| 10 | factor 5 excess with spontaneous thrombosis | 96.86% | DL |
| 11 | severe nonproliferative diabetic retinopathy | 95.99% | DL |
| 12 | thrombophilia | 95.61% | DL |
| 13 | amenorrhea (disease) | 95.46% | DL |
| 14 | zinc, elevated plasma | 94.91% | DL |
| 15 | infectious bovine rhinotracheitis | 94.59% | DL |
| 16 | malignant catarrh | 94.59% | DL |
| 17 | primary release disorder of platelets | 94.36% | DL |
| 18 | kidney pelvis sarcomatoid transitional cell carcinoma | 93.79% | DL |
| 19 | prostatic urethra urothelial carcinoma | 93.70% | DL |
| 20 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 93.69% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.